Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Refractory Soft Tissue Sarcoma
NCT06110650Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of surufatinib in soft tissue sarcoma (STS), sponsored by Fudan University. Status: unknown.
02
Drugs
surufatinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06110650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110650.